Swiss National Bank Trims Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Swiss National Bank decreased its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 8.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 71,900 shares of the company’s stock after selling 6,700 shares during the quarter. Swiss National Bank’s holdings in Kiniksa Pharmaceuticals were worth $1,422,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in KNSA. China Universal Asset Management Co. Ltd. increased its stake in shares of Kiniksa Pharmaceuticals by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after acquiring an additional 1,004 shares in the last quarter. Franklin Resources Inc. grew its holdings in Kiniksa Pharmaceuticals by 1.7% in the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock worth $1,798,000 after purchasing an additional 1,100 shares during the period. New York State Common Retirement Fund increased its stake in shares of Kiniksa Pharmaceuticals by 12.4% during the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock valued at $302,000 after purchasing an additional 1,680 shares in the last quarter. Quarry LP purchased a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at approximately $50,000. Finally, Martingale Asset Management L P boosted its position in shares of Kiniksa Pharmaceuticals by 6.8% in the 3rd quarter. Martingale Asset Management L P now owns 48,460 shares of the company’s stock worth $1,211,000 after purchasing an additional 3,083 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Trading Down 1.2 %

Shares of KNSA opened at $23.09 on Friday. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -164.92 and a beta of 0.48. The business’s fifty day simple moving average is $20.77 and its two-hundred day simple moving average is $22.00. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. During the same quarter in the previous year, the business posted $0.35 earnings per share. Kiniksa Pharmaceuticals’s quarterly revenue was up 46.9% compared to the same quarter last year. As a group, research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Analyst Ratings Changes

KNSA has been the subject of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Citigroup began coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a “buy” rating and a $40.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $37.17.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,879 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total value of $205,104.90. Following the transaction, the chief financial officer now directly owns 23,382 shares of the company’s stock, valued at approximately $540,124.20. This trade represents a 27.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the sale, the chief operating officer now directly owns 81,975 shares of the company’s stock, valued at $1,604,250.75. The trade was a 14.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 93,766 shares of company stock worth $2,011,735 over the last three months. 54.57% of the stock is currently owned by company insiders.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.